Cannabix Technologies Comments on Legalization of Marijuana in Canada, Impaired Driving and Workplace Safety

Vancouver, British Columbia, October 16, 2018 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace provides the following statement related to the legalization of marijuana for recreational use across Canada: “The introduction of legalized marijuana use in Canada is a watershed moment as it relates to public safety on our roads and workplaces. Cannabix applauds the significant efforts that are underway by the Government of Canada and others to increase public awareness of the dangers of drugged driving on our roadways and the acute problems of being under the influence of drugs in the workplace. A recent survey by the Angus Reid Institute (dated September 25, 2018) finds a majority of Canadians lack confidence in the ability of their community police to assess and punish those driving under the influence of marijuana. Furthermore, according to MADD Canada, drugs are present in fatal crashes nearly twice as often as alcohol and that Canada’s existing system does a very poor job of detecting drivers under the influence of drugs (news release May 29, 2018). The Human Resources Professionals Association in January 2018, conducted a survey in Ontario and found that 71 per cent of its members do not feel prepared for legalization, with almost 48 per cent citing concerns about ensuring a safe workplace. As the issue of drugged driving and influence of drugs in the workplace becomes increasingly acute, Cannabix is using its technology, research and development (R&D) and scientific experience to develop effective tools to aid law enforcement and help governments and the public transition to marijuana legalization in various jurisdictions. Cannabix Technologies has been on the forefront in R&D to create an accurate breath test for ∆9-tetrahydrocannabinol - the psychoactive component of marijuana that causes impairment. We believe that establishing point-of-care breath testing technology for cannabis is the future for law enforcement and workplace testing, as it is non-invasive, will be easy to use, and will look to provide superior sensitivity to help better determine impairment.  Cannabix is a well funded Canadian company that is rapidly developing marijuana breathalyzer technology.
 
Cannabix has been building upon its promising characterization results from August and with a secondary bench version device to establish repeatable results in multiple devices.  Thus far testing has demonstrated the ability to isolate ∆9-tetrahydrocannabinol (“THC”) and suppress background substrates and scientists are continuously working to improve resolving power. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of THC.
 
FAIMS works as an “ion blocking” technology, essentially blocking unwanted ions/analytes and allowing specified ions to pass through for detection. The characterization work has been conducted using a bench version of the FAIMS device. Cannabix scientists have been actively tuning the FAIMS device coupled to real time switchable mass spectrometry to detect key molecules and their complex pathways in the body to enable the identification of recency of use.  

The Company also reports that it has short listed 2 potential medical device development companies in order to develop the next version of the device as well as create multiple devices, that would be used for pilot testing.